SCHEMBL3571744

SCHEMBL3571744

COc1ccc(-c2cc3c4cc(C5=NN=C(N)C5=O)ccc4n(C)c3n(C)c2=O)c(OC)c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.37
▸ NPSR1 Q6W5P4 3/20 0.37
▸ MAPT P10636 3/20 0.37
▸ MAPK1 P28482 2/20 0.37
▸ APAF1 O14727 1/20 0.37
▸ PABPC1 P11940 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ IDO1 P14902 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MCL1 Q07820 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.37
▸ P2RX3 P56373 3/20 0.37
▸ KDM4E B2RXH2 4/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP3A4 P08684 1/20 0.35
▸ NTRK1 P04629 2/20 0.35
▸ HTT P42858 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ GFER P55789 1/20 0.34
▸ NR4A2 P43354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573768 0.83 CRHR1 (0.35) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL3568345 0.80 CNR1 (0.39) ALDH1A1KDM4EGAAHPGDHSD17B10
SCHEMBL2381071 0.75 KDM4E (0.44) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL4775814 0.75 ALDH1A1 (0.44) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL3564916 0.75 MAPT (0.48) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL3572244 0.72 MAPT (0.44) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL3569243 0.69 CNR1 (0.38) ALDH1A1NPSR1MAPTKDM4EGAA
SCHEMBL2384414 0.69 PADI4 (0.44) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL1338786 0.69 L3MBTL1 (0.50) ALDH1A1NPSR1MAPTMAPK1APAF1
SCHEMBL2385324 0.69 ALDH1A1 (0.47) ALDH1A1NPSR1MAPTMAPK1APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7812165-B2 6-substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2010-10-12 — — US disclosed
EP-1742947-B1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2008-08-20 — — EP disclosed
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof SANOFI-AVENTIS (FR) 2007-06-07 — — US disclosed
EP-1742947-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF Sanofi-Aventis (FR) 2007-01-17 — — EP disclosed
WO-2005108398-A1 6-SUBSTITUTED PYRIDOINDOLONE DERIVATIVES PRODUCTION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2005-11-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129365-A1 6-Substituted pyridoindolone derivatives, production and therapeutic use thereof PNPO, CYP2D6, DPYD ALDH1A1 628/4885NPSR1 947/4885MAPT 1004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback